Tilt a flavin
How GSK has solved the hydrogen peroxide byproduct problem of KMO inhibitors
A team from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of Edinburgh has solved a problem that has stymied the development of kynurenine 3-monoxygenase (KMO) inhibitors -- the production of cytotoxic hydrogen peroxide -- and generated a series of compounds ripe for preclinical testing.
Last year in a Nature Medicine study led by Damian Mole, the collaborators identified KMO as a therapeutic target in mouse and rat models of acute pancreatitis, and reported results for a first-generation, oxazolidinone-based KMO inhibitor in those models (see Distillery). The team also reported results for a series of benzisoxazole-based KMO inhibitors in a Journal of Medicinal Chemistry study in March. KMO metabolizes kynurenine, which is elevated in blood of patients with severe acute pancreatitis, and the resulting metabolite causes cell damage and apoptosis...
BCIQ Target Profiles